Suzie ChenProfessor Rutgers – Ernest Mario School of PharmacyEOHSI – Toxicology
The main interest in my laboratory is to study the molecular mechanisms of melanoma development using a line of transgenic mice (TG-3) generated in my lab several years ago. From mapping studies, we have determined that about 70 kb of host sequences have been deleted by the insertion of the transgene. The host DNA had been deleted from a region of mouse chromosome 10 which is syntenic to the long arm of human chromosome 6. This region of human chromosome 6 has been shown to be highly rearranged in a large number of human nonfamilial malignant melanomas. A combination of techniques were used to identify intron 3 of metabotropic glutamate receptor 1 (Grm1) as the gene disrupted by the insertion of the transgene. The metabotropic glutamate receptors (mGluRs) belong to a family of seven transmembrane domain, G-protein coupled receptors (GPCRs). Expression of mGluRs is usually restricted to neuronal cells, but the signaling pathways activated by these receptors are widely distributed in both neural and non-neural cells. Mice with null mutations in Grm1 display reductions in hippocampal long term potentiation, and abnormalities of motor coordination and associative learning. In the TG-3 line, we showed that Grm1 is expressed only in ear tumors, but not normal ear as demonstrated by semi-quantitative RT-PCR, Western immunoblots, immunofluorescence and immunohistochemistry. Co-localization of Grm1 and the melanocyte-marker Tyrp-1 was detected only in tumors and not in the normal counterparts. Based on these results, a new transgenic line was generated with targeted Grm1 expression to melanocytes, by using Grm1 cDNA under the melanocyte-specific Dct (dopachrome tautomerase) promoter. Founder of Dct-Grm1 exhibited melanotic tumors on the tail at 7.5 months of age. High levels of Grm1 expression were observed in tail tumors but not in normal tail. Histopathological analysis showed these tumors to be very similar to those of TG-3. These results provide the compelling evidence suggesting the improtance of Grm1 signaling in melanocytic neoplasia.
Together with Dr. J. Goydos at CINJ, we begin to explore the potential role of the aberrant expression of Grm1 in human melanoma development and progression. Our data on human melanoma biopsy samples (7/19) showed expression of Grm1. Grm1 expression was not detected in two benign nevi and one normal skin samples. Similar analyses were also done with 18 human melanoma cell lines, 12/18 of these cell lines showed Grm1 expression, these results were confirmed by immunofluorescence. Co-localization of Grm1 and Tyrp1 (a melanocyte-specific marker) was detected only in lines that also showed Grm1 expression.
- Melanoma research
- Melanoma research from bench to the clinic.
- 2014 – present Council member of PanAmerican Society for Pigment Cell Research
- 2011 – present VA Oncology Study Section
- 2004 – present Member, NCI Special Emphasis Panel
- 2000 – present Planning and Review Committee for the Annual Retreat on Cancer Research
- 2004-2010 National Institute of Health Grant
- 2007-2012 National Institute of Health Grant
- 2009-2011 State of New Jersey Commission on Cancer Research Grant
- Dolfi, SC, Medina, DJ, Kareddula, A, Paratala, B, Rose, A, Dhami, J, Chen, S, Ganesan, S, Mackay, G, Vazquez, A et al.. Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells. Oncotarget. 2017;8 (27):44639-44653. doi: 10.18632/oncotarget.17961. PubMed PMID:28591718 PubMed Central PMC5546507
- Isola, AL, Chen, S. Extracellular vesicles: important players in immune homeostasis. Ann Transl Med. 2017;5 (Suppl 1):S16. doi: 10.21037/atm.2017.03.76. PubMed PMID:28567398 PubMed Central PMC5440304
- Kulkarni, A, Al-Hraishawi, H, Simhadri, S, Hirshfield, KM, Chen, S, Pine, S, Jeyamohan, C, Sokol, L, Ali, S, Teo, ML et al.. BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAF(V600E) Mutant Melanoma. Clin. Cancer Res. 2017;23 (18):5631-5638. doi: 10.1158/1078-0432.CCR-16-0758. PubMed PMID:28539463
- Isola, AL, Eddy, K, Chen, S. Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma. Cancers (Basel). 2016;8 (12):. doi: 10.3390/cancers8120110. PubMed PMID:27941674 PubMed Central PMC5187508
- Isola, AL, Chen, S. Exosomes: The Messengers of Health and Disease. Curr Neuropharmacol. 2017;15 (1):157-165. . PubMed PMID:27568544 PubMed Central PMC5327461
- Hirshfield, KM, Tolkunov, D, Zhong, H, Ali, SM, Stein, MN, Murphy, S, Vig, H, Vazquez, A, Glod, J, Moss, RA et al.. Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. Oncologist. 2016; :. doi: 10.1634/theoncologist.2016-0049. PubMed PMID:27566247 PubMed Central PMC5189630
- Boregowda, RK, Medina, DJ, Markert, E, Bryan, MA, Chen, W, Chen, S, Rabkin, A, Vido, MJ, Gunderson, SI, Chekmareva, M et al.. The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma. Oncotarget. 2016;7 (20):29689-707. doi: 10.18632/oncotarget.8822. PubMed PMID:27102439 PubMed Central PMC5045426